Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aprea Therapeutics Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is distributed across 2 distinct examiners, indicating a focused but divided workload at the patent office. All current matters are concentrated within 1 distinct art unit, suggesting a narrow technical focus for the company's recent filings. This concentration in the 1 distinct art unit may allow for a more predictable prosecution environment despite the involvement of multiple individuals.
The busiest examiner for this portfolio is SHIAO, REI TSANG, who is responsible for 1 pending office action. This individual workload represents 1 of the 2 pending office actions for the company. Practitioners should note that the 2 distinct examiners are operating within the same art unit, which may lead to consistent examination standards across the pending applications. Managing the workload requires careful coordination to ensure that arguments made to SHIAO, REI TSANG are consistent with those presented to the other examiner. This strategy is essential for maintaining a cohesive patent strategy in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565598 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 53d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565598 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 53d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18855713 | ATR INHIBITORS | SHIAO, REI TSANG | — | §103 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18565598 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS WEE1 KINASE INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103§112 | Non-Final OA | 53d | Pending | Nov 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial